KR19980031367A - Method for preparing amlodipine besylate - Google Patents
Method for preparing amlodipine besylate Download PDFInfo
- Publication number
- KR19980031367A KR19980031367A KR1019960050918A KR19960050918A KR19980031367A KR 19980031367 A KR19980031367 A KR 19980031367A KR 1019960050918 A KR1019960050918 A KR 1019960050918A KR 19960050918 A KR19960050918 A KR 19960050918A KR 19980031367 A KR19980031367 A KR 19980031367A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- amlodipine besylate
- amlodipine
- methanol
- benzenesulfonic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/06—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of zinc, cadmium or mercury
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/14—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of germanium, tin or lead
Abstract
본 발명은 하기 화학식 2의 아지드 화합물을 금속 또는 금속염 촉매하에서 2당량 이상의 벤젠술폰산과 반응시켜 하기 화학식 1의 암로디핀 베실레이트를 제조하는 방법을 제공한다.The present invention provides a method for preparing amlodipine besylate of formula 1 by reacting an azide compound of formula 2 with two or more equivalents of benzenesulfonic acid under a metal or metal salt catalyst.
[화학식 1][Formula 1]
[화학식 2][Formula 2]
본 발명에 의하면 상기 화학식 2의 아지드 화합물의 환원반응에 벤젠술폰산을 양성자원(proton source)으로 사용함으로써, 단일공정에 의하여 고수율로 화학식 1의 화합물을 제조할 수 있다.According to the present invention, by using benzenesulfonic acid as a proton source in the reduction reaction of the azide compound of Formula 2, the compound of Formula 1 can be prepared in a high yield by a single process.
Description
본 발명은 허혈 및 고혈압 치료제로서 유용한 하기 화학식 1의 암로디핀 베실레이트의 새로운 제조방법에 관한 것이다.The present invention relates to a novel process for the preparation of amlodipine besylate of formula (1), which is useful as a therapeutic agent for ischemia and hypertension.
암로디핀 베실레이트는 하기 화학식 3으로 표시되는 암로디핀의 벤젠술폰산염으로서, 화학명은 3-에틸 5-메틸 모노벤젠술포네이트이고, 장기간에 걸쳐 활성을 나타내는 강력한 칼슘 통로 차단제(Calcium Channel Blocker)이다.Amlodipine besylate is a benzenesulfonate salt of amlodipine represented by the following formula (3), and its chemical name is 3-ethyl 5-methyl monobenzenesulfonate, and is a strong calcium channel blocker that shows activity over a long period of time.
화학식1Formula 1
[화학식 3][Formula 3]
암로디핀베실레이트 자체는 이미 공지이며, 여러가지 제조방법들이 소개되어 있다.Amlodipine besylate itself is already known, and various preparation methods have been introduced.
먼저, 대한민국 특허공고 제 87-809호에는 암로디핀(화학식 3)을 제조할 수 있는 여러 가지 방법들이 개시되어 있다. 예를 들어, 화학식 2의 아지드 화합물을, 트리페닐포스핀이나 아연 및 염산, 또는 H2/Pd 등으로 환원시켜 암로디핀(A)을 제조한다. 제조된 암로디핀(A)을 정제하기 위하여, 말레인산을 부가하여 암로디핀말레이트로 전환하고, 이를 다시 염기로 처리하여 유리형태의 정제된 암로디핀(화학식 3)을 얻을 수 있다.First, Korean Patent Publication No. 87-809 discloses various methods for preparing amlodipine (Formula 3). For example, amlodipine (A) is prepared by reducing an azide compound of formula (2) with triphenylphosphine, zinc and hydrochloric acid, H 2 / Pd, or the like. In order to purify the prepared amlodipine (A), maleic acid may be added to convert to amlodipine maleate, which may then be treated with a base to obtain purified amlodipine (Formula 3) in free form.
[반응식 1]Scheme 1
그리고, 대한민국 특허공고 제 95-6710호에서는, 암로디핀의 여러 가지 염들 중에서 암로디핀 베실레이트가 특이하게 우수한 약제학적 특성을 갖는다고 밝히고, 그 제조방법으로서 유리염기 형태의 암로디핀(화학식 3)을 불활성용매 중에서 벤젠 술폰산 또는 그의 암모늄염 용액과 반응시켜 생성된 암로디핀 베실레이트를 회수하는 방법을 개시하고 있다.In addition, Korean Patent Publication No. 95-6710 discloses that amlodipine besylate has a particularly excellent pharmaceutical property among various salts of amlodipine, and as a preparation method, amlodipine (formula 3) in free base form in an inert solvent is disclosed. A method of recovering the resulting amlodipine besylate by reaction with benzene sulfonic acid or its ammonium salt solution is disclosed.
이러한 종래 방법으로 암로디핀 베실레이트를 제조하기 위해서는,하기의 반응식 2에 의한 바와 같이 먼저 아지드화합물(화학식 2)을 환원시켜 암로디핀 염기(A)를 제조하고, 이어서 암로디핀말레이트를 이용하여 정제된 유리형태의 암로디핀을 얻은 다음, 이를 다시 벤젠 술폰산과 반응시켜 암로디핀 베실레이트를 수득하게 된다.In order to prepare amlodipine besylate by this conventional method, as shown in Scheme 2 below, the azide compound (Formula 2) is first reduced to prepare amlodipine base (A), followed by purified glass using amlodipine maleate. Amlodipine in the form is obtained and then reacted with benzene sulfonic acid again to obtain amlodipine besylate.
[반응식 2]Scheme 2
따라서, 적어도 4단계 이상의 공정을 거쳐야 하므로 제조과정이 복잡할 뿐아니라, 그 과정에서 목적물의 수율이 떨어지게 된다는 등의 문제점이 있었다.Therefore, there is a problem that the manufacturing process is not only complicated, but the yield of the target product falls in the process because it must go through at least four steps.
한편, EP 899,200에는 암로디핀의 아미노기를 트리틸기로 보호한 상태에서, 벤젠술폰산으로 처리한 후 트리틸기를 제저함으로써 암로디핀 베실레이트를 제조하는 방법이 기재되어 있다.EP 899,200, on the other hand, describes a process for producing amlodipine besylate by treating benzenesulfonic acid and then removing the trityl group while protecting the amino group of amlodipine with a trityl group.
[반응식 3]Scheme 3
그러나 이러한 방법에서도, 아미노기를 보호하는 공정이 추가되는 등, 공정이 번거롭고, 수율도 저조한 문제점이 있었다.However, even in such a method, there is a problem that the process is cumbersome and the yield is low, such as the addition of a step of protecting the amino group.
이에, 본 발명에서는 종래기술이 가지는 문제점을 해결하여 보다 단축된 공정에 의하여 고수율로 암로디핀 베실레이트를 제조하는 방법을 제공하고자 한다.Accordingly, the present invention is to solve the problems of the prior art to provide a method for producing amlodipine besylate in a high yield by a shorter process.
이를 위하여 본 발명에 의하여 하기 화학식 2의 아지드 화합물[3-에틸 금속 또는 금속염 촉매하에서 2당량 이상의 벤젠술폰산과 반응시키는 것을 특징으로하는 화학식 1의 암로디핀 베실레이트의 제조방법이 제공된다.To this end, the present invention provides a process for preparing amlodipine besylate of formula (1), wherein the azide compound of formula (2) is reacted with at least two equivalents of benzenesulfonic acid under a 3-ethyl metal or metal salt catalyst.
이하, 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.
금속 또는 금속염 촉매로는 주석이나 아연, 철, 마그네슘, 염화주석 이수화물, 팔라디움 등을 사용할 수 있으나, 이 중에서 주석 또는 아연을 사용하는 것이 바람직하다. 금속 또는 금속염 촉매는 출발물질(화학식 2) 1몰당 2당량 이상을 사용하는 것이 바람직하다.As the metal or metal salt catalyst, tin, zinc, iron, magnesium, tin chloride dihydrate, palladium, or the like may be used. Of these, tin or zinc is preferably used. The metal or metal salt catalyst is preferably used at least 2 equivalents per mole of the starting material (Formula 2).
본 발명의 방법에 있어서는 통상의 유기용매 또는 유기용매와 물과의 혼합용매를 반응용매로 사용할 수 있다. 유기용매의 예로는, 메탄올, 에탄올, 이소프로판올, 테트라하이드로푸란, 디옥산 및 아세토니트릴 등을 들 수 있다. 특히, 바람직한 용매는 메탄올, 에탄올, 이소프로판올과 같은 알코올류와 테트라하이드로푸란이다.In the method of the present invention, a conventional organic solvent or a mixed solvent of organic solvent and water can be used as the reaction solvent. Examples of the organic solvent include methanol, ethanol, isopropanol, tetrahydrofuran, dioxane, acetonitrile and the like. Particularly preferred solvents are alcohols such as methanol, ethanol and isopropanol and tetrahydrofuran.
본 발명의 중요한 특징은 아지드기를 포함하는 출발물질(화학식 2)을 환원하기 위하여 벤젠술폰산을 사용하는 데 있다. 벤젠술폰산은 종래 암로디핀을 암로디핀 베실레이트로 전환하는 염생성 반응에 사용하였으나, 본 발명에서는 화학식 2의 아지드 화합물의 환원 반응에서 양성자원을 제공하는 역할을 하며, 이로써 아지드화합물을 환원함과 동시에 베실레이트로 전환시킴으로써 단일 공정에 의하여 고수율로 화학식 1의 화합물을 수득하게 된다. 벤젠술폰산은 출발물질(화학식 2) 1몰당 2당량 이상을 사용하는 것이 바람직하다. 반응은 통상 환류온도 및 환류조건하에서 수행한다.An important feature of the present invention is the use of benzenesulfonic acid to reduce the starting material (Formula 2) containing an azide group. Benzenesulfonic acid has conventionally been used in the salting reaction for converting amlodipine to amlodipine besylate, but in the present invention serves to provide a positive resource in the reduction reaction of the azide compound of formula (2), thereby reducing the azide compound Conversion to besylate yields the compound of formula 1 in high yield by a single process. Benzene sulfonic acid is preferably used at least 2 equivalents per mole of the starting material (Formula 2). The reaction is usually carried out under reflux temperature and reflux conditions.
본 발명에 따른 화합물의 제조방법을 하기의 실시예로써 보다 상세히 설명한다. 그러나, 이들 실시예에 의하여 본 발명의 범위를 제한하고자 하는 것은 아니다.The preparation method of the compound according to the present invention will be described in more detail by the following examples. However, these examples are not intended to limit the scope of the present invention.
실시예 1Example 1
3-에틸 5-메틸(±) 0.87g을 메탄올 30ml에 가하고, 환류시켜 녹인 다음 주석 분진 0.71g을 가하였다. 이 혼합물에, 90% 벤젠술폰산 1.40g을 메탄올 20ml에 녹인 용액을 천천히 적가한 후 30분간 비등환류시키고, 뜨거운 상태에서 여과하여 불용성 물질을 제거한 다음 감압증류하여 농축시켰다. 이 잔류물을 에테르 100ml에서 교반하고, 여과하여 침전물을 얻었다. 이 침전물을 다시 물 10ml에서 교반한 후 여과하여 건조시켰다. 건조된 생성물을 메탄올에서 재결정시켜서 3-에틸 5-메틸 모노벤젠술포네이트 1.02g을 수득하였다.(수율: 90%) 융점: 198~200℃0.87 g of 3-ethyl 5-methyl (±) was added to 30 ml of methanol, dissolved in reflux and 0.71 g of tin dust was added thereto. To this mixture, a solution of 1.40 g of 90% benzenesulfonic acid dissolved in 20 ml of methanol was slowly added dropwise, followed by boiling under reflux for 30 minutes, filtered to remove an insoluble substance, and then concentrated by distillation under reduced pressure. This residue was stirred in 100 ml of ether and filtered to give a precipitate. The precipitate was again stirred in 10 ml of water and then filtered and dried. The dried product was recrystallized in methanol to give 1.02 g of 3-ethyl 5-methyl monobenzenesulfonate (yield: 90%). Melting point: 198 to 200 ° C.
실시예 2Example 2
3-에틸 5-메틸 0.87g을 메탄올 30ml에 가하고, 환류시켜 녹인 다음 주석 분진 0.48g을 가하였다. 이 혼합물에, 90% 벤젠술폰산 1.40g을 메탄올 20ml에 녹인 용액을 천천히 적가한 후 30분간 비등환류시키고, 뜨거운 상태에서 여과하여 불용성 물질을 제거한 다음 감압증류하여 농축시켰다. 이 잔류물을 에테르 100ml에서 교반하고, 여과하여 침전물을 얻었다. 이 침전물을 다시 물 10ml에서 교반한 후 여과하여 건조시켰다. 건조된 생성물을 메탄올에서 재결정시켜서 3-에틸 5-메틸 모노벤젠설포네이트 0.99g을 수득하였다.(수율: 87%)0.87 g of 3-ethyl 5-methyl was added to 30 ml of methanol, dissolved under reflux and 0.48 g of tin dust was added thereto. To this mixture, a solution of 1.40 g of 90% benzenesulfonic acid dissolved in 20 ml of methanol was slowly added dropwise, followed by boiling under reflux for 30 minutes, filtered to remove an insoluble substance, and then concentrated by distillation under reduced pressure. This residue was stirred in 100 ml of ether and filtered to give a precipitate. The precipitate was again stirred in 10 ml of water and then filtered and dried. The dried product was recrystallized in methanol to give 0.99 g of 3-ethyl 5-methyl monobenzenesulfonate (yield: 87%).
융점: 198~200℃Melting Point: 198 ~ 200 ℃
실시예 3Example 3
3-에틸 5-메틸 0.87g을 메탄올 30ml에 가하고, 환류시켜 녹인 다음 아연 분진 0.31g을 가하였다. 이 혼합물에, 90% 벤젠술폰산 1.40g을 메탄올 20ml에 녹인 용액을 천천히 적가한 후 30분간 비등환류시키고, 뜨거운 상태에서 여과하여 불용성 물질을 제거한 다음 감압증류하여 농축시켰다. 이 잔류물을 에테르 100ml에서 교반하고, 이 혼합물에 물 10ml을 가한 다음 다시 교반한 후 여과하여 건조시켰다. 건조된 생성물을 메탄올에서 재결정시켜서 3-에틸 5-메틸 모노벤젠술포네이트 0.94g을 수득하였다. (수율 :84%)0.87 g of 3-ethyl 5-methyl was added to 30 ml of methanol, dissolved under reflux, and 0.31 g of zinc dust was added thereto. To this mixture, a solution of 1.40 g of 90% benzenesulfonic acid dissolved in 20 ml of methanol was slowly added dropwise, followed by boiling under reflux for 30 minutes, filtered to remove an insoluble substance, and then concentrated by distillation under reduced pressure. The residue was stirred in 100 ml of ether, and 10 ml of water was added to the mixture, followed by stirring again, followed by filtration and drying. The dried product was recrystallized in methanol to give 0.94 g of 3-ethyl 5-methyl monobenzenesulfonate. (Yield: 84%)
융점: 198~200℃Melting Point: 198 ~ 200 ℃
실시예 4Example 4
3-에틸 5-메틸 0.87g을 메탄올 30ml에 가하고, 환류시켜 녹인 다음 아연 분진 0.46g을 가하였다. 이 혼합물에, 90% 벤젠술폰산 1.40g을 메탄올 20ml에 녹인 용액을 천천히 적가한 후 30분간 비등환류시키고, 뜨거운 상태에서 여과하여 불용성 물질을 제거한 다음 감압증류하여 농축시켰다. 이 잔류물을 에테르 100ml에서 교반하고, 여과하여 침전물을 얻었다. 이 침전물을 다시 물 10ml에서 교반한 후 여과하여 건조시켰다. 건조된 생성물을 메탄올에서 재결정시켜서 3-에틸 5-메틸 모노벤젠술포네이트 0.89g을 수득하였다.(수율: 79%) 융점: 198~200℃0.87 g of 3-ethyl 5-methyl was added to 30 ml of methanol, dissolved under reflux, and 0.46 g of zinc dust was added thereto. To this mixture, a solution of 1.40 g of 90% benzenesulfonic acid dissolved in 20 ml of methanol was slowly added dropwise, followed by boiling under reflux for 30 minutes, filtered to remove an insoluble substance, and then concentrated by distillation under reduced pressure. This residue was stirred in 100 ml of ether and filtered to give a precipitate. The precipitate was again stirred in 10 ml of water and then filtered and dried. The dried product was recrystallized in methanol to give 0.89 g of 3-ethyl 5-methyl monobenzenesulfonate (yield: 79%). Melting point: 198 to 200 ° C.
본 발명에 의하면 암로디핀의 전구체로부터 환원하여 말레이트를 제조하는 단계와 그 염을 유리염기 형태로 분리하는 종래 방법에 의한 두 단계의 공정을 생략하고, 아지드기를 포함하는 암로디핀을 출발물질(화학식 2)로하여 직접 암로디핀 베실레이트를 합성하므로, 단축된 공정에 의하여 간단하게, 종래의 방법에 의한 경우보다 월등히 향상된 수율로 암로디핀 베실레이트를 제조할 수 있다.According to the present invention, a step of preparing maleate by reducing from a precursor of amlodipine and omitting two steps by a conventional method of separating the salt into a free base form is omitted, and amlodipine including an azide group is used as a starting material. Since amlodipine besylate is directly synthesized, the amlodipine besylate can be prepared by a shortened process simply with a much improved yield than the conventional method.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019960050918A KR100217240B1 (en) | 1996-10-31 | 1996-10-31 | Preparation of amlodipine besylate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019960050918A KR100217240B1 (en) | 1996-10-31 | 1996-10-31 | Preparation of amlodipine besylate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR19980031367A true KR19980031367A (en) | 1998-07-25 |
| KR100217240B1 KR100217240B1 (en) | 1999-09-01 |
Family
ID=19480200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960050918A KR100217240B1 (en) | 1996-10-31 | 1996-10-31 | Preparation of amlodipine besylate |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100217240B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100374767B1 (en) * | 2001-03-13 | 2003-03-03 | 한미약품공업 주식회사 | Improved method of preparing amlodipine |
| KR101125123B1 (en) * | 2008-12-04 | 2012-03-16 | 화일약품주식회사 | Method of preparing S---amlodipine with high optical purity and intermediate compound produced during the same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100467669B1 (en) * | 2002-08-21 | 2005-01-24 | 씨제이 주식회사 | An organic acid salt of amlodipine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950006710A (en) * | 1993-08-03 | 1995-03-21 | 이헌조 | Orientation apparatus of magnetic recording medium |
-
1996
- 1996-10-31 KR KR1019960050918A patent/KR100217240B1/en not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100374767B1 (en) * | 2001-03-13 | 2003-03-03 | 한미약품공업 주식회사 | Improved method of preparing amlodipine |
| KR101125123B1 (en) * | 2008-12-04 | 2012-03-16 | 화일약품주식회사 | Method of preparing S---amlodipine with high optical purity and intermediate compound produced during the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100217240B1 (en) | 1999-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL202805B1 (en) | Improved process for preparing nitrogen−substituted aminotetralins | |
| JPS6168469A (en) | Manufacture of 6-chloro-n-methyl-2,3,4,5-tetrahydro-1h- 3-benzazepine | |
| JPH09255651A (en) | Production of n-methyl-n'-nitroguanidine | |
| KR19980031367A (en) | Method for preparing amlodipine besylate | |
| US6559319B2 (en) | Synthesis of compounds useful in the manufacture of ketorolac | |
| CN113372281A (en) | Synthetic method of metronidazole | |
| JP2578797B2 (en) | Method for producing N- (sulfonylmethyl) formamides | |
| KR100374405B1 (en) | A new process for amlodipine besylate | |
| US5973155A (en) | Process for preparing (-)-trans-N-p-fluorobenzoylmethyl-4-(p-fluorophenyl)-3-[[3,4-(methylened ioxy)phenoxy]methyl]-piperidine | |
| EP0344675B1 (en) | Method for the production of selegiline hydrochloride | |
| JPS6028822B2 (en) | Method for producing 4-methylimidazole-5-carboxylic acid isopropyl ester | |
| EP4071139A1 (en) | Crystalline lofexidine hydrochloride | |
| KR100448640B1 (en) | Method for producing phenyl propionic acid derivatives with high yield and purity | |
| CN109384734B (en) | Preparation method of Selsemipa intermediate | |
| KR100448642B1 (en) | Method for producing phenyl propionic acid derivatives from 2-phenylpropionic acid by simple processing steps with high yield and purity | |
| JPH11292869A (en) | Production of ipriflavone | |
| KR100297802B1 (en) | Method for preparing 2- (3-trifluoromethyl) anilinonicotinic acid 2- (N-morpholine) ethyl. | |
| WO2020129591A1 (en) | Production method for amide alcohol compound | |
| KR100448641B1 (en) | Method for producing phenyl propionic acid derivatives from 2-phenylpropionic acid by simple processing steps with high yield | |
| JP3547497B2 (en) | Method for producing benzothiazolone compound | |
| JP2023503647A (en) | Process for the preparation of novel crystalline forms of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea | |
| KR100277671B1 (en) | (-)-Trans-ene-pi-fluorobenzoylmethyl-4- (pi-fluorophenyl) -3-[[3,4- (methylenedioxy) phenoxy] methyl] -piperidine and pharmaceutically acceptable Method for preparing added salt | |
| KR100288404B1 (en) | 2-Benzothiazolyl 4-amino-5-chloro-2-methoxythiobenzoate And Process For Preparing Cisapride Employing The Same | |
| WO2023100110A1 (en) | Process for preparing brivaracetam | |
| CN117142999A (en) | Racemization method of drug intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20080331 Year of fee payment: 10 |
|
| LAPS | Lapse due to unpaid annual fee |